Niagen Bioscience, Inc. current report, 09 December 2020

SEC Filing Summary: ChromaDex Corporation (CDXC)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on December 9, 2020. The filing serves as a Regulation FD disclosure regarding a corporate presentation released by the Company. This presentation was made available on the Company's website and utilized for the December 2020 Benzinga Small Cap Conference held virtually on the same date.

Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document functions as a notice of a presentation rather than a financial report containing audited or unaudited financial statements.

Material Changes

No material changes to financial performance or operations are detailed within the text of this specific filing. The filing references an attached Exhibit 99.1 (Investor Presentation) which may contain such data, but the text of the 8-K itself does not summarize these figures.

Guidance, Outlook, and Risks

The filing explicitly states that the information contained in the report and the attached presentation is being "furnished" and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the content is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are enumerated in the body of this report.

Key Facts for Investor Verification

  • Verify the contents of the attached Exhibit 99.1 (Investor Presentation) for actual financial data and strategic outlook, as the 8-K text only announces its release.
  • Confirm that the presentation materials are not legally "filed" with the SEC and do not carry the same liability protections as standard financial reports.
  • Note that the registrant is ChromaDex Corporation, trading under the symbol CDXC on the Nasdaq Capital Market.
  • Check the Company's website for the full corporate presentation referenced in Item 7.01.